Table 11.
Ongoing phase II trials of anti-PD-1/PD-L1 in gynecological cancers (not including novel combination therapy)
| ID | Cancer/condition | No. | Start date | Intervention | Design | Status |
|---|---|---|---|---|---|---|
| NCT02725489 | Women’s cancers | 13 | 2016.6 | Durvalumab | Non-randomized parallel | Not yet recruiting |
| NCT02811497 METADUR | OC/platinum-resistant recurrent | 60 | 2016.9 | Durvalumab + azacitidine | Single group | Recruiting |
| NCT03899610 | OC/advanced | 24 | 2019.7 | Durvalumab + tremelimumab + chemotherapy | Single group | Recruiting |
| NCT03357757 LATENT | Virus associated cancer | 39 | 2018.2 | Avelumab + valproic acid | Single group | Recruiting |
| NCT03503786 MITO END-3 | EC/advanced or recurrent | 120 | 2018.4 | Avelumab + PC vs. avelumab | Randomized parallel | Not yet recruiting |
| NCT02440425 | OC/platinum-resistant recurrent | 43 | 2015.8 | Pembrolizumab + paclitaxel | Single group | Active, not recruiting |
| NCT02635360 | CC/advanced | 88 | 2016.1 | Pembrolizumab maintenance/throughout, plus chemoradiation | Randomized parallel | Recruiting |
| NCT02608684 PemCiGem | OC/platinum-resistant recurrent | 21 | 2016.2 | Pembrolizumab + standard treatment | Single group | Active, not recruiting |
| NCT02530154 | OC/stage III–IV | 30 | 2016.7 | Pembrolizumab + PC | Single group | Recruiting |
| NCT02899793 | EC/recurrent or metastatic | 25 | 2016.9 | Pembrolizumab | Single group | Recruiting |
| NCT02865811 | OC/platinum-resistant recurrent | 26 | 2016.9 | Pembrolizumab + doxorubicin | Single group | Active, not recruiting |
| NCT02901899 | OC/recurrent | 38 | 2016.11 | Pembrolizumab + gemcitabine | Single group | Recruiting |
| NCT02900560 | OC/platinum-resistant recurrent | 34 | 2016.12 | Pembrolizumab + azacytidine vs. pembrolizumab | Non-randomized parallel | Active, not recruiting |
| NCT02834975 | OC/advanced | 40 | 2016.12 | Pembrolizumab + PC | Single group | Recruiting |
| NCT03192059 PRIMMO | CC or EC | 43 | 2017.7 | Pembrolizumab | Single group | Recruiting |
| NCT02549209 | EC/recurrent | 46 | 2017.8 | Pembrolizumab + PC | Single group | Recruiting |
| NCT03126812 | OC/stage IV | 15 | 2017.11 | Pembrolizumab as neoadjuvant | Single group | Recruiting |
| NCT03275506 NEOPEMBROV | OC/stage IV | 45 | 2018.2 | Pembrolizumab + chemotherapy vs. chemotherapy | Non-randomized parallel | Recruiting |
| NCT03029403 | OC/advanced | 42 | 2018.2 | Pembrolizumab + DPX-Survivac (vaccine) + cyclophosphamide | Non-randomized parallel | Recruiting |
| NCT03410784 MITO28 | OC/advanced | 72 | 2018.4 | Pembrolizumab + PC | Single group | Not yet recruiting |
| NCT03276013 TOPIC | EC/advanced, recurrent or metastatic | 51 | 2018.5 | Pembrolizumab + doxorubicin | Single group | Recruiting |
| NCT03539328 MITO27 | OC/platinum-resistant recurrent | 138 | 2018.6 | Pembrolizumab + chemotherapy vs. chemotherapy | Randomized parallel | Not yet recruiting |
| NCT03732950 | OC/recurrent | 30 | 2019.3 | Pembrolizumab | Single group | Recruiting |
| NCT03430700 PROMPT | OC/platinum-resistant recurrent | 28 | 2019.5 | Pembrolizumab + paclitaxel | Single group | Recruiting |
| NCT04375956 | OC/platinum-resistant recurrent | 100 | 2020.5 | Pembrolizumab | Single group | Not yet recruiting |
| NCT04238988 | CC/locally advanced | 45 | 2020.3 | Pembrolizuma + PC | Single group | Not yet recruiting |
| NCT03340376 | CC/recurrent | 48 | 2017.8 | Atezolizumab vs. atezolizumab + doxorubicin vs. doxorubicin | Randomized parallel | Recruiting |
| NCT03612791 | CC/advanced | 190 | 2018.6 | Atezolizumab + radiotherapy vs. radiotherapy | Randomized parallel | Recruiting |
| NCT03614949 | CC/recurrent, persistent, or metastatic | 26 | 2019.1 | Atezolizumab | Single group | Recruiting |
| NCT02498600 | OC/recurrent | 96 | 2015.6 | Nivolumab vs. nivolumab + ipilimumab | Randomized parallel | Active, not recruiting |
| NCT03241745 | EC/metastatic or recurrent | 40 | 2017.8 | Nivolumab | Single group | Recruiting |
| NCT03808857 | CC/recurrent or metastatic | 80 | 2019.2 | GB226 | Single group | Recruiting |
| NCT03972722 | CC/recurrent or metastatic | 89 | 2019.5 | GLS-010 | Single group | Recruiting |
| NCT04188860 | CC/recurrent | 34 | 2019.12 | Camrelizumab + paclitaxel | Single group | Recruiting |
| NCT04368273 | CC/advanced | 30 | 2020.5 | Toripalimab | Single group | Not yet recruiting |
| NCT03104699 | CC/advanced | 211 | 2017.4 | Balstilimab | Single group | Active, not recruiting |